Skip to main content
Clinical Trials/NCT00830622
NCT00830622
Completed
Not Applicable

A Targeted Cell Phone Intervention to Improve Patient Access to Care and Drug Adherence in Patients Taking Antiretroviral (ARV) Medications in Kenya

University of Manitoba1 site in 1 country536 target enrollmentMay 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV
Sponsor
University of Manitoba
Enrollment
536
Locations
1
Primary Endpoint
Adherence to ART and HIV RNA suppression
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

A clinical study to evaluate the use of cell phones to support drug adherence and follow-up of patients taking antiretroviral therapy (ART) for treatment of HIV. The intervention involves health-care providers sending regular short-message-service (SMS) text messages to patients and following up their responses. The hypothesis is that the cell phone intervention will improve ART adherence and health outcomes compared with the current standard of care.

Detailed Description

This RCT study focuses on enrolling and following patients initiating ART. Note, a second parallel prospective cohort study enrolls and follows ART experienced patients who have already been taking ART for at least one year before and after the same intervention.

Registry
clinicaltrials.gov
Start Date
May 2007
End Date
March 2010
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • HIV infected and starting antiretroviral therapy
  • Adequate (daily) access to a cell phone
  • Intending to attend the enrollment clinic for 2 years
  • Consent to participate

Exclusion Criteria

  • Not meeting inclusion criteria

Outcomes

Primary Outcomes

Adherence to ART and HIV RNA suppression

Time Frame: 6,12 months

Although many patients are seen every 3 months, study visits with questionnaires and viral load are completed at 0, 6, and 12 month scheduled follow-up visits.

Secondary Outcomes

  • Retention(6, 12 months)
  • Quality of Life (SF-12)(3, 6, 9, 12 months)
  • Health (CD4, weight, progression to AIDS, all cause mortality)(6, 12 months)

Study Sites (1)

Loading locations...

Similar Trials